Review of Ophthalmology backs home IOP

Glaucoma monitoring is basically a data problem. Doctors are trying to protect the optic nerve from slow, irreversible damage, but most patients only get a pressure check every four to six months and formal structural or functional testing a few times a year. Review of Ophthalmology’s April 9 piece leans hard into that gap and says home monitoring is starting to look less like a gimmick and more like a practical add-on for real care. ### What changed here? The news is not that glaucoma can suddenly be managed entirely from the couch. The shift is that a mainstream ophthalmology trade publication is now treating home monitoring as part of the near-term toolkit — especially for intraocular pressure, or IOP, and for repeat functional testing outside the clinic. That is a more concrete stance than the old “interesting, maybe someday” framing. ### Why is glaucoma such a bad fit for snapshot care? Because the disease moves slowly, unevenly, and often invisibly. A single office reading can look fine while pressure spikes happen at night, early in the morning, or on days the patient is nowhere near the clinic. The optic nerve and visual field also change over long stretches, so sparse testing can delay the moment when progression becomes obvious enough to act on. ### What does home IOP monitoring actually add? More measurements, taken in real life, at times clinics usually miss. In the Review of Ophthalmology summary, home rebound tonometry is the most mature piece of the stack. One cited study found the mean daily maximum IOP beat the maximum clinic IOP in 44% of patients, and exceeded target IOP by 3, 5, or outside normal office hours. ### Is the home tonometer accurate enough? Accurate enough to be useful, but not perfect enough to replace clinic gold standards. The Review article says iCare Home devices generally correlate well with Goldmann applanation tonometry, but often read a bit lower or otherwise differ by a couple of mmHg. A 2023 feasibility study reached the same basic conventional testing with Goldmann. ### Can patients really do this themselves? Often yes — but not universally. In that 2023 study, 72.9% of trained participants were able to take reliable readings at home. That is good enough to matter clinically, but it also tells you the catch: this is not a frictionless consumer gadget. Training, dexterity, vision, comfort with the device, and follow-through all shape whether the data will be usable. ### What about home optic nerve imaging? This is where the story gets more forward-looking. The broader glaucoma-telehealth literature keeps pointing to a three-part remote stack: IOP, visual fields, and structural imaging of the optic nerve or retina. But home imaging is less established than home tonometry. Review of Ophthalmology’s piece is strongest when talking about remote testing as a landscape in motion, not a finished standard of care. ### So who benefits first? Probably the patients who are hardest to understand with occasional office snapshots — people with suspected pressure spikes outside clinic hours, complex glaucoma, postoperative questions, or signs of progression despite “controlled” office pressures. Busy practices benefit too, but the bigger point is not convenience. It is catching the disease when the disease is actually doing something. ### Bottom line? Home glaucoma monitoring is moving from experimental side project toward selective routine use. But this is an extra lens on the disease — not a replacement for exams, imaging, and clinician judgment. The real promise is simple: fewer blind spots between visits.